373,231 Shares in Indivior PLC (NASDAQ:INDV) Bought by Foursixthree Capital LP

Foursixthree Capital LP purchased a new position in shares of Indivior PLC (NASDAQ:INDV - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 373,231 shares of the company's stock, valued at approximately $4,639,000. Indivior comprises 1.6% of Foursixthree Capital LP's holdings, making the stock its 8th biggest holding. Foursixthree Capital LP owned about 0.27% of Indivior as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Indivior during the fourth quarter worth approximately $56,000. Stifel Financial Corp grew its position in Indivior by 24.0% during the 4th quarter. Stifel Financial Corp now owns 12,675 shares of the company's stock worth $158,000 after purchasing an additional 2,450 shares during the last quarter. Jane Street Group LLC acquired a new position in Indivior in the third quarter valued at $180,000. Rathbones Group PLC raised its holdings in shares of Indivior by 11.6% in the fourth quarter. Rathbones Group PLC now owns 14,284 shares of the company's stock valued at $183,000 after buying an additional 1,483 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Indivior during the fourth quarter worth about $359,000. Institutional investors and hedge funds own 60.33% of the company's stock.

Indivior Price Performance

NASDAQ INDV traded down $0.28 on Tuesday, hitting $11.62. 258,953 shares of the company's stock were exchanged, compared to its average volume of 981,436. The firm's 50-day moving average price is $9.82 and its two-hundred day moving average price is $10.49. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -33.22 and a beta of 0.98. Indivior PLC has a fifty-two week low of $7.33 and a fifty-two week high of $18.59.

Indivior (NASDAQ:INDV - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported $0.41 EPS for the quarter, beating analysts' consensus estimates of $0.22 by $0.19. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. The company had revenue of $266.00 million during the quarter, compared to the consensus estimate of $240.13 million. On average, research analysts predict that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on INDV shares. Rodman & Renshaw began coverage on Indivior in a research report on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price target on the stock. RODMAN&RENSHAW upgraded Indivior to a "strong-buy" rating in a research note on Tuesday, January 28th. Finally, Piper Sandler lowered their price objective on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a research report on Thursday, March 6th.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.